The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.
 
Nan Zhang
No Relationships to Disclose
 
Jiongyuan Li
No Relationships to Disclose
 
Mingjian Piao
No Relationships to Disclose
 
Chengjie Li
No Relationships to Disclose
 
Ziyu Xun
No Relationships to Disclose
 
Longhao Zhang
No Relationships to Disclose
 
Yanyu Wang
No Relationships to Disclose
 
Kai Liu
No Relationships to Disclose
 
Shanshan Wang
No Relationships to Disclose
 
Hanping Wang
No Relationships to Disclose
 
Hai-Tao Zhao
No Relationships to Disclose